{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:02:15Z","timestamp":1789527735099,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcp.2019.04.027","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T11:05:30Z","timestamp":1556276730000},"page":"230-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Treatment of giant cell arteritis"],"prefix":"10.1016","volume":"165","author":[{"given":"Miguel \u00c1.","family":"Gonz\u00e1lez-Gay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinitario","family":"Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Prieto-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Calderon-Goercke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-1328","authenticated-orcid":false,"given":"Oreste","family":"Gualillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.04.027_b0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0889-857X(05)70232-5","article-title":"Epidemiology of the vasculitides","volume":"27","author":"Gonz\u00e1lez-Gay","year":"2001","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.bcp.2019.04.027_b0015","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/md.0b013e31803d1764","article-title":"Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study","volume":"86","author":"Gonzalez-Gay","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":"Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2017.98","article-title":"Visual loss and other cranial ischaemic complications in giant cell arteritis","volume":"13","author":"Soriano","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0035","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients","volume":"79","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","article-title":"Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis","volume":"88","author":"Gonzalez-Gay","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0050","first-page":"1326","article-title":"The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study","volume":"26","author":"Gonz\u00e1lez-Gay","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0055","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.027_b0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semarthrit.2003.09.007","article-title":"Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions","volume":"33","author":"Gonzalez-Gay","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narvaez","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0070","first-page":"1750","article-title":"Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica","volume":"25","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","article-title":"Disease pattern in cranial and large-vessel giant cell arteritis","volume":"42","author":"Brack","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"2 Suppl 89","key":"10.1016\/j.bcp.2019.04.027_b0080","article-title":"Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review","volume":"33","author":"Loricera","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0085","article-title":"Predictors of positive (18)F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica","author":"Prieto-Pe\u00f1a","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0090","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","article-title":"BSR and BHPR guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.04.027_b0095","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.md.0000145366.40805.f8","article-title":"Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.md.0000180043.19285.54","article-title":"Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0110","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/art.20523","article-title":"Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population","volume":"51","author":"Gonzalez-Gay","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.20231","article-title":"Giant cell arteritis without clinically evident vascular involvement in a defined population","volume":"51","author":"Gonzalez-Gay","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0120","first-page":"1186","article-title":"The diagnosis and management of patients with giant cell arteritis","volume":"32","author":"Gonzalez-Gay","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0125","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semarthrit.2017.08.009","article-title":"(18)F-FDG PET\/CT in the follow-up of large-vessel vasculitis: a study of 37 consecutive patients","volume":"47","author":"Mart\u00ednez-Rodr\u00edguez","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sarh.2002.50025","article-title":"Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica","volume":"33","author":"Gonz\u00e1lez-Gay","year":"2003","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0145","first-page":"2413","article-title":"Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis","volume":"31","author":"Amoli","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2015.02.009","article-title":"A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility","volume":"96","author":"Carmona","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2019.04.027_b0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2016.11.013","article-title":"A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis","volume":"100","author":"Carmona","year":"2017","journal-title":"Am. J. Hum. Genet."},{"issue":"6 Suppl 36","key":"10.1016\/j.bcp.2019.04.027_b0160","first-page":"S18","article-title":"Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica","volume":"22","author":"Gonzalez-Gay","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0165","first-page":"1737","article-title":"A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis","volume":"32","author":"Rueda","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/BOR.0000000000000068","article-title":"Infectious triggers for vasculitis","volume":"26","author":"van Timmeren","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0175","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2019.04.027_b0180","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.38631","article-title":"In search of a candidate pathogen for giant cell arteritis: sequencing based characterization of the giant cell arteritis microbiome","volume":"66","author":"Bhatt","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/ar3358","article-title":"Giant cell arteritis: immune and vascular aging as disease risk factors","volume":"13","author":"Mohan","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2019.04.027_b0190","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/annrheumdis-2014-207116","article-title":"DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis","volume":"75","author":"Coit","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"suppl 2","key":"10.1016\/j.bcp.2019.04.027_b0200","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1093\/rheumatology\/kex423","article-title":"Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved","volume":"57","author":"Terrades-Garcia","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.04.027_b0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF03401699","article-title":"Giant cell vasculitis is a T cell-dependent disease","volume":"3","author":"Brack","year":"1997","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.revmed.2009.12.020","article-title":"T(H)17 lymphocytes: induction, phenotype, functions, and implications in human disease and therapy","volume":"32","author":"Samson","year":"2011","journal-title":"Rev. Med. Intern."},{"key":"10.1016\/j.bcp.2019.04.027_b0215","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/annrheumdis-2015-208371","article-title":"Blocking interferon gamma reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis","volume":"75","author":"Corbera-Bellalta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2016.05.008","article-title":"Involvement and prognosis value of CD8(+) T cells in giant cell arteritis","volume":"72","author":"Samson","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2019.04.027_b0225","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.autrev.2010.05.002","article-title":"Pathogenesis of giant cell arteritis: more than just an inflammatory condition?","volume":"9","author":"Ly","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2019.04.027_b0230","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0002-9440(10)65175-9","article-title":"Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells","volume":"155","author":"Kaiser","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2019.04.027_b0235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/annrheumdis-2012-201309","article-title":"IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis","volume":"72","author":"Ciccia","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0240","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2010.11.001","article-title":"Chronic treatment with PDGF-BB and endothelin-1 synergistically induces vascular hyperplasia and loss of contractility in organ-cultured rat tail artery","volume":"214","author":"Kida","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bcp.2019.04.027_b0245","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis","volume":"76","author":"Planas-Rigol","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/res.90.3.251","article-title":"Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly","volume":"90","author":"Galis","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.04.027_b0255","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/08916930903002495","article-title":"Vascular damage in giant cell arteritis","volume":"42","author":"Piggott","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bcp.2019.04.027_b0260","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.bcp.2019.04.027_b0265","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0270","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.160466","article-title":"Giant cell arteritis: Visual loss Is our major concern","volume":"43","author":"Gonzalez-Gay","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11926-014-0480-1","article-title":"Giant cell arteritis and polymyalgia rheumatica: an update","volume":"17","author":"Gonz\u00e1lez-Gay","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bcp.2019.04.027_b0280","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bcp.2019.04.027_b0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/1744666X.2018.1485491","article-title":"Current and emerging diagnosis tools and therapeutics for giant cell arteritis","volume":"14","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2019.04.027_b0290","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10067-013-2384-2","article-title":"Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis","volume":"33","author":"Yates","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0295","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0300","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0305","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0310","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.027_b0315","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0320","article-title":"The role of biologics in the treatment of giant cell arteritis","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bcp.2019.04.027_b0325","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14656566.2018.1501360","article-title":"Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update","volume":"19","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2019.04.027_b0330","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0335","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/rheumatology\/35.7.702","article-title":"Low-dose corticosteroids and blindness in giant cell arteritis","volume":"35","author":"Gonz\u00e1lez-Gay","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0340","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11926-010-0135-9","article-title":"Giant cell arteritis: epidemiology, diagnosis, and management","volume":"12","author":"Gonzalez-Gay","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bcp.2019.04.027_b0345","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/21678707.2016.1244480","article-title":"Managing of giant cell arteritis and polymyalgia rheumatica","volume":"4","author":"Gonz\u00e1lez-Gay","year":"2016","journal-title":"Expert Opin. Orphan. Drugs."},{"key":"10.1016\/j.bcp.2019.04.027_b0350","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","article-title":"Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature","volume":"80","author":"Hayreh","year":"2002","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.bcp.2019.04.027_b0355","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0360","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0365","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/00002512-200623080-00002","article-title":"Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management","volume":"23","author":"Gonzalez-Gay","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bcp.2019.04.027_b0370","first-page":"277","article-title":"Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients","volume":"19","author":"Gonz\u00e1lez-Gay","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0375","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000070631","article-title":"Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies","volume":"217","author":"Hayreh","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.bcp.2019.04.027_b0385","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","article-title":"Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain","volume":"90","author":"Martinez-Lado","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.04.027_b0390","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0395","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0400","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0405","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.027_b0410","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0415","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2019.04.027_b0420","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Hernandez-Rodriguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.04.027_b0425","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0430","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s002960050019","article-title":"Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis","volume":"17","author":"Field","year":"1997","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bcp.2019.04.027_b0435","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0440","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomized controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0445","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0450","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1084\/jem.179.3.951","article-title":"Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes","volume":"179","author":"Weyand","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2019.04.027_b0455","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1172\/JCI117428","article-title":"Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease","volume":"94","author":"Wagner","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.04.027_b0460","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/acr.20043","article-title":"Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis","volume":"62","author":"Garcia-Martinez","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.bcp.2019.04.027_b0465","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32835b133a","article-title":"New treatment strategies in large-vessel vasculitis","volume":"25","author":"Unizony","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0475","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.4414\/smw.2011.13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.bcp.2019.04.027_b0480","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.04.027_b0485","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bcp.2019.04.027_b0490","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients","volume":"43","author":"R\u00e9gent","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0495","unstructured":"D. Prieto-Pe\u00f1a, J. Loricera, M. Calder\u00f3n-Goercke, I. Mart\u00ednez-Rodr\u00edguez, J. Banzo, B. Atienza, et al., Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET\/CT. Abstract Supplement 2018 ACR\/ARHP Annual Meeting. Arthritis Rheumatol. 70 (2018) Abstract Number 2748."},{"key":"10.1016\/j.bcp.2019.04.027_b0500","first-page":"79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3 Suppl 97","key":"10.1016\/j.bcp.2019.04.027_b0505","first-page":"S44","article-title":"Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review","volume":"34","author":"Loricera","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.bcp.2019.04.027_b0515","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2019.04.027_b0520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.04.027_b0525","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0530","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double blind trial of Abatacept (CTLA-4Ig) for the treatment of Giant Cell Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0535","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.40105","article-title":"Abatacept as adjunctive therapy for the treatment of giant cell arteritis: comment on the article by Langford et al","volume":"69","author":"De Boysson","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.04.027_b0540","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211622","article-title":"Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis","volume":"77","author":"Samson","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0545","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.04.027_b0550","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","volume":"81","author":"Ly","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bcp.2019.04.027_b0555","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2019.04.027_b0560","unstructured":"B. Hartmann, J. Liao, M.H. Weisman, K.J. Warrington, J.J. Goronzy, C.M. Weyand, The STAT1 Signaling Pathway In Giant Cell Arteritis. Meeting: 2013 ACR\/ARHP Annual Meeting. (2013) Abstract Number: 1691."},{"key":"10.1016\/j.bcp.2019.04.027_b0565","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.04.027_b0570","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:10:11Z","timestamp":1757769011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":114,"alternative-id":["S0006295219301625"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}